Bhavesh Borate on Muck Rack

Bhavesh Borate

As seen in: Nature, Cell Press
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Bhavesh

Contact Bhavesh, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Correlates of severe and delta COVID-19 in a phase 3 trial of the AZD1222 vaccine

|
By Holly Janes, Youyi Fong, Ying Huang, David Benkeser, Elizabeth Kelly, Ian Hirsch, Ann Marie Stanley, Tonya L Villafana, Christos Petropoulos, Andrew Leith, Bill Webb, Yiwen Lu Verified, Chenchen Yu, Bhavesh Borate, Nima Hejazi, April K. Randhawa, Michele Andrasik, James G. Kublin, Margaret Brewinski Isaacs, Tina Tong, Merlin L. Robb, Lawrence Corey, Kathleen M. Neuzil, Dean Follmann, Ann R Falsey, Magdalena E. Sobieszczyk, Richard A. Koup, Peter Gilbert, Deanne Haugaard, Lars W. P. van der Laan, Mamodikoe Makhene
| Nature Verified
Abstract In the phase 3 AZD1222 COVID-19 vaccine trial, anti-Spike (vaccine-matched and Delta) binding IgG antibody concentration and neutralizing antibody (nAb) titer (vaccine-matched+D614G and Delta), measured four weeks post-dose two (D57), were assessed as correlates of risk of severe COVID-19 and Delta COVID-19 over ~4 to ~13 months (severe) or ~11 months (Delta) post-D57.
Open in Who Shared Issue with article?

Cytomegalovirus viral load kinetics as surrogate endpoints after allogeneic transplantation

|
By Elizabeth R. Duke, Brian Williamson, Bhavesh Borate, Jonathan Golob
| The Journal of Clinical Investigation
Clinical MedicineIn-Press PreviewClinical trialsInfectious disease Free access | 10.1172/JCI133960 Elizabeth R. Duke,1 Brian D. Williamson,2 Bhavesh Borate,3 Jonathan L. Golob,1 Chiara Wychera,4 Terry Stevens-Ayers,1 Meei-Li Huang,5 Nicole Cossrow,6 Hong Wan,7 T. Christopher Mast,6 Morgan A. Marks,8 Mary Flowers,9 Keith R. Jerome,5 Lawrence Corey,10 Peter B. Gilbert,1 Joshua T.
Open in Who Shared Issue with article?

A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge

|
By Amarendra Pegu, Yunda Huang, Bhavesh Borate
| Cell Press Verified
Highlights • Meta-analysis of NHP studies administering a single bNAb before SHIV challenge • Serum neutralizing titers correlate strongly with protection against SHIV infection • ID50, ID80, and IIP all predict protection, with ID50 and ID80 stronger predictors • Substantial levels of neutralization might be needed for protection by a single bNAb Summary Passively administered broadly neutralizing antibodies (bNAbs) targeting the HIV-1 envelope glycoprotein (Env) have been shown to protect...
Open in Who Shared Issue with article?
See all 3 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified